
-
VistaGen Therapeutics NasdaqCM:VTGN Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Location: 343 Allerton Avenue, South San Francisco, CA, 94080, United States | Website: https://www.vistagen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-15.85M
Cash
88.56M
Avg Qtr Burn
-9.755M
Short % of Float
2.36%
Insider Ownership
0.26%
Institutional Own.
53.52%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fasedienol (PH94B) Details Social Anxiety Disorder | Phase 3 Data readout | |
Itruvone, PH10 (pherine nasal spray ) Details Major depressive disorder | Phase 2b Initiation | |
PH80 ( nasal spray ) Details Menopause, Hot flashes | Phase 2b Initiation | |
PH284 (nasal spray) Details Cancer cachexia | Phase 2a Update | |
PH15 (pherine nasal spray) Details Cognitive Dysfunction | Phase 2a Update | |
Fasedienol (PH94B) (pherine nasal spray) Details Adjustment Disorder | Phase 2a Update | |
AV-101(4-Cl-KYN) (targets the NMDAR) Details Major depressive disorder | Phase 2a Update |